JP2022153638A5 - - Google Patents

Download PDF

Info

Publication number
JP2022153638A5
JP2022153638A5 JP2022124557A JP2022124557A JP2022153638A5 JP 2022153638 A5 JP2022153638 A5 JP 2022153638A5 JP 2022124557 A JP2022124557 A JP 2022124557A JP 2022124557 A JP2022124557 A JP 2022124557A JP 2022153638 A5 JP2022153638 A5 JP 2022153638A5
Authority
JP
Japan
Prior art keywords
dosage form
bupropion
disorders include
humans
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022124557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022153638A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/019445 external-priority patent/WO2019165379A1/en
Application filed filed Critical
Publication of JP2022153638A publication Critical patent/JP2022153638A/ja
Publication of JP2022153638A5 publication Critical patent/JP2022153638A5/ja
Pending legal-status Critical Current

Links

JP2022124557A 2018-02-23 2022-08-04 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 Pending JP2022153638A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US62/634,718 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US62/794,469 2019-01-18
US201962809480P 2019-02-22 2019-02-22
US62/809,480 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion
JP2020544420A JP2021513998A (ja) 2018-02-23 2019-02-25 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020544420A Division JP2021513998A (ja) 2018-02-23 2019-02-25 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形

Publications (2)

Publication Number Publication Date
JP2022153638A JP2022153638A (ja) 2022-10-12
JP2022153638A5 true JP2022153638A5 (cg-RX-API-DMAC7.html) 2022-12-02

Family

ID=67688503

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544420A Pending JP2021513998A (ja) 2018-02-23 2019-02-25 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形
JP2022124557A Pending JP2022153638A (ja) 2018-02-23 2022-08-04 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法
JP2024041381A Pending JP2024075655A (ja) 2018-02-23 2024-03-15 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020544420A Pending JP2021513998A (ja) 2018-02-23 2019-02-25 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024041381A Pending JP2024075655A (ja) 2018-02-23 2024-03-15 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法

Country Status (19)

Country Link
EP (1) EP3755312A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021513998A (cg-RX-API-DMAC7.html)
KR (3) KR20240091043A (cg-RX-API-DMAC7.html)
CN (2) CN112087999A (cg-RX-API-DMAC7.html)
AU (3) AU2019223187B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092076A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002166A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200415A (cg-RX-API-DMAC7.html)
EC (1) ECSP20060179A (cg-RX-API-DMAC7.html)
IL (2) IL276871B2 (cg-RX-API-DMAC7.html)
MA (1) MA51914A (cg-RX-API-DMAC7.html)
MX (2) MX2020008704A (cg-RX-API-DMAC7.html)
MY (1) MY202993A (cg-RX-API-DMAC7.html)
NI (1) NI202000056A (cg-RX-API-DMAC7.html)
NZ (1) NZ767378A (cg-RX-API-DMAC7.html)
PE (1) PE20211752A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008056SA (cg-RX-API-DMAC7.html)
WO (1) WO2019165379A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
CN114423417A (zh) * 2019-09-20 2022-04-29 艾克萨姆治疗公司 用于对映体富集的或纯的安非他酮的剂型和方法
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
KR20250114110A (ko) 2022-11-28 2025-07-28 안테씨프 바이오벤쳐스 투 엘엘씨 약물 활성의 조절제로서의 부프로피온
WO2025259728A1 (en) * 2024-06-13 2025-12-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
EP3981403A1 (en) * 2013-11-05 2022-04-13 Antecip Bioventures II LLC Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
MX2013014166A (es) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Enantiomeros activos y sus sales para el tratamiento de la obesidad.
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Similar Documents

Publication Publication Date Title
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
TWI335217B (en) Pharmaceutical formulations of modafinil
AU2016256779B2 (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
JP2024074963A5 (cg-RX-API-DMAC7.html)
US11938139B2 (en) Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
JPWO1993011765A1 (ja) (+)アポビンカミン酸2−ニトロキシエチルエステルの新規な用途
JP2023535744A5 (cg-RX-API-DMAC7.html)
JP2024069192A5 (cg-RX-API-DMAC7.html)
JP2022514089A5 (cg-RX-API-DMAC7.html)
JP2003503450A5 (cg-RX-API-DMAC7.html)
JP2006506378A5 (cg-RX-API-DMAC7.html)
JP2025020117A5 (cg-RX-API-DMAC7.html)
JP2009529502A5 (cg-RX-API-DMAC7.html)
NZ767378A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
JP2021530541A5 (cg-RX-API-DMAC7.html)
JP2018507243A5 (cg-RX-API-DMAC7.html)
JPH0269413A (ja) アレルギー性鼻炎の治療方法
JP2023500032A5 (cg-RX-API-DMAC7.html)
JP2023530120A5 (cg-RX-API-DMAC7.html)
JP2020522560A5 (cg-RX-API-DMAC7.html)
JP2014515397A (ja) 自閉症の治療における使用のためのクレンブテロール
JP2020526575A5 (cg-RX-API-DMAC7.html)
CN105025880A (zh) 用于施用活性成分的盖仑氏形式
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2021530568A5 (cg-RX-API-DMAC7.html)